







Update

Welcome to the May newsletter! We are fast approaching our 1 year anniversary of opening the trial and we wanted to thank our participating sites for your continued support.



Remember, if you have any

questions to get in touch:

endonet@nds.ox.ac.uk.

Trial Progress

Congratulations to **University Hospital Llandough** who are the latest centre to open to recruitment!

EndoNET is looking for additional hospitals to take part. If you are interested in joining the 30+ UK hospitals that will be recruiting, contact us on: <u>endonet@nds.ox.ac.uk</u>.

We have just had our best recruitment month to date and with 13 UK now hospitals open, we're looking forward to the next year!

EndoNET Trial Team

Important Reminder

Our discussions with sites and review of the screening logs indicate that patients may be concerned about taking part in EndoNET due to the prospect of



- It is important for us to continually improve and provide the best treatments for patie
- I would like to discuss a study that you are eligible for, called the Endoniel study.
 EndoNET is looking at different approaches to treating this specific type of breast called the study.
- We know for certain that there are good treatments available for this type of cancer: endocrine treatment and surgery. We are confident these treatments will help.
- We are less sure about the best order in which to give these treatments. This is what the EndoNET study is a ming to find out.
- We at [hosp/tal name] are one of many hospitals across the UK who are part of EndoNET to answe this important question.

Explaining the treatment arms in a balanced way
 You have a strengty eestrogen receptor positive cancer, which means the tumour is highly sensitive
 to endocrine treatment. We therefore recommend endocrine treatment for 5–10 years, to lower the
 risk of the cancer coming back.



Recruitment continues to pick up with 9 of our centres now randomising patients. Congratulations to **Basildon Hospital** who are currently our top recruiter!

EndoNET Randomisations



delaying their surgery.

We want to remind you that it's important to open-up the conversation, suggesting taking a 'step back' and exploring the patients' concerns.

We have recently launched the **QRI hint and tips document** and **flash cards** to help!

Important Events for the Calendar



- We also recommend that you have surgery to remove the cancer.
- No matter what, you will be offered both surgery and endocrine treatment, because we know these are effective for you.
- To shrink the tumour some of this endocrine treatment can also be given before surgery. This may
- mean that patients do not have to have as big an operation and more of the breast can be preserved.
- Whilst both approaches are recommended as options in national guidance we do not know for sure if one approach is better than the other.
- tis is why we are running the EndoNET study. The study compares two different arrangements for aur treatment schedule, which are equally suitable for you:
- In treatment arm 1, you'll start endocrine treatment immediately and proceed to have surgery in 2-4 weeks. You'll then take endocrine treatment for 5-10 years.
- In treatment arm 2, you'll start endoorine treatment immediately and then continue it for 6 months with a view to shrinking the turnour before surgery, with scans during that time to ensure the turnour is responding as expected. You'll have surgery at 6 months. You'll then take endocrine treatment for 5-10 years.



Update on Amendment 004

We submitted Amendment 004 to include patients with T-stage 1 tumours ≥ 15mm in January 2023.



Unfortunately there have been delays with the MHRA Approvals due to a national backlog of amendments. We'll be in touch as soon as it can be implemented!

Microsoft Teams.

Investigator Meeting sign-up:

JUNE 2023

EndoNET Investigator Meeting Monday 5th June, 10.00-14.00 Ashmolean Museum, Oxford

Travel grants available!



ABS Conference 2023

EndoNET will be at the ICC Belfast for ABS Conference 2023 from 15-16th May.



Look out for us and take part in our conference activity & grab some trial merch.

Funder, Sponsor and Key Affiliations

Funder: NIHR HTA Programme

Sponsor: University of Oxford

Trials Units: Surgical Interventions Trials Unit (NDS SITU)

and Oxford Clinical Trials Research Unit (OCTRU).

Contact Us

Contact our trial inbox on <u>endonet@nds.ox.ac.uk</u>.

Follow us on Twitter @EndoNET_Trial for live trial updates and news.

EndoNET Newsletter - May 2023 Update